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Abstract
Background: The total intake of dietary antioxidants may reduce prostate cancer risk but available data are sparse
and the possible role of supplements unclear. We investigated the potential association between total and dietary
antioxidant intake and prostate cancer in a Swedish population.
Methods: We used FFQ data from 1499 cases and 1112 controls in the population based case–control study
Cancer of the Prostate in Sweden (CAPS). The ferric reducing antioxidant potential (FRAP) assay was used to assess
the total antioxidant capacity (TAC) of diet and supplements. We calculated odds ratios (ORs) for the risk of prostate
cancer across quintiles of antioxidant intake from all foods, from fruit and vegetables only, and from dietary
supplements using unconditional logistic regression.
Results: Coffee comprised 62 % of the dietary antioxidant intake, tea 4 %, berries 4 %, chocolate 2 %, and boiled
potatoes 2 %. In total 19 % and 13 % of the population took multivitamins and supplemental Vitamin C
respectively, on a regular basis. Antioxidant intake from all foods and from fruits and vegetables separately
measured by the FRAP assay was not associated with prostate cancer risk. For antioxidant intake from supplements
we found a positive association with total, advanced, localized, high grade and low grade prostate cancer in those
above median supplemental TAC intake of users compared to non-users (Adjusted ORs for total prostate cancer: 1.
37, 95 % CI 1.08–1.73, advanced: 1.51, 95 % CI 1.11–2.06, localized: 1.36. 95 % CI 1.06–1.76, high grade 1.60, 95 % CI
1.06–2.40, low grade 1.36, 95 % CI 1.03–1.81). A high intake of coffee (≥6 cups/day) was associated with a possible
risk reduction of fatal and significantly with reduced risk for high grade prostate cancer, adjusted OR: 0.45 (95 % CI:
0.22–0.90), whereas a high intake of chocolate was positively associated with risk of total, advanced, localized and
low grade disease (adjusted OR for total: 1.43, 95 % CI 1.12–1.82, advanced: 1.40, 95 % CI 1.01–1.96, localized: 1.43,
95 % CI 1.08–1.88, low-grade: 1.41, 95 % CI 1.03–1.93).
Conclusions: Total antioxidant intake from diet was not associated with prostate cancer risk. Supplement use may
be associated with greater risk of disease.
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Background
The potential cancer protective effect of diets rich in anti-
oxidants has been extensively studied in relation to different
cancer sites. Most observational studies and intervention,
have examined the effect of either single or a few antioxi-
dant compounds, or a combined score of redox active com-
pounds, but no consistent protective effect of antioxidant
intake on prostate cancer has been shown [1–5].
Because naturally occurring antioxidants in, for example,
fruits and vegetables work in a network of redox active
compounds, it could be more informative and potentially
reduce confounding by other effects of redox active com-
pounds to study the total intake of antioxidants. Several
methods have been developed to quantify total dietary anti-
oxidant content [6]. We used the Ferric-reducing ability of
plasma (FRAP) assay, a fast, easy to use, and reproducible
method to assess total antioxidant content (TAC) in foods,
beverages and supplements [7]. We recently reported that
total antioxidant intake from diet reduced risk of total, le-
thal and advanced prostate cancer in the Health Profes-
sionals Follow-up Study [8]. We found a weak protective
effect of total antioxidant intake from diet, as well as for
coffee, one of the largest contributors to antioxidant intake.
On the other hand, total antioxidant intake from supple-
ments increased risk for lethal and advanced prostate can-
cer [6, 8].
In the current study, we examined the association be-
tween total antioxidant capacity (TAC) from diet and
supplements and prostate cancer in a large population
based case–control study of prostate cancer in Sweden.
This study points out some differences in antioxidant in-
take between a Scandinavian and a US population, whilst




The Cancer of the Prostate in Sweden (CAPS) study is a
population-based case–control study of prostate cancer
as described previously [9, 10]. Cases from four of the
six regional cancer registries in Sweden were recruited
through treating physicians in 2001 and 2002. After ap-
proval from patients to participate, they were mailed a
letter including consent form and included in the study
when they filled out a self-administered questionnaire
about lifestyle factors (including diet) and family history
or donated blood samples which were returned to the
study administration. The cancer was histopathologically
or cytologically verified. Disease-related information,
such as TNM (tumor, node, metastasis) status, clinical
stage, Gleason score, and serum prostate-specific antigen
(PSA) level at diagnosis was obtained from the National
Prostate Cancer Registry and was available for 95 % of
the cases. Controls were randomly selected from the
Swedish population registry, identified by personal iden-
tification number, and frequency-matched to cases by
age in 5-year age categories and by region of residence
of the cases. When controls had been identified, they
were contacted by mail, receiving a letter describing the
study. A few weeks later they received the same letter
with self-administered questionnaire and equipment for
blood sampling as the cases. Linking control subjects
with the National Cancer Registry identified potential
control subjects with previous prostate cancer history.
who were excluded. Of 1895 invited prostate cancer
cases, 1499 (79 %) completed the detailed baseline ques-
tionnaire about lifestyle and health. Average time be-
tween date of diagnosis and date when the questionnaire
was sent was 5 months. Of the 1684 invited controls,
1130 (67 %) completed the questionnaire. All partici-
pants gave informed consent at the time of enrollment
in the study. The ethics committees at Karolinska Insti-
tutet and Umeå University in Sweden approved the
study.
Dietary assessment
Dietary data were collected as part of the questionnaire.
All participants completed a validated, self-administered
109-item food frequency questionnaire (FFQ) that
assessed the participants’ frequency of consumption of
foods and beverages over the previous 12 months. The
questionnaire included ten additional questions on diet-
ary supplements. This included information about fre-
quency, dosage, type of supplement and duration of use.
A shorter version of the FFQ had been validated earlier
against weighed food records among women, and found
correlations among the major contributors to TAC ran-
ging from 0.32 to 0.71 [11]. Each FFQ item was assigned
a FRAP value based on the average value of a limited
number of variants of each food item, specified in the
Antioxidant Food Table [7, 12] and foods specifically an-
alyzed for this study (Additional file 1). For combined
items such as berries, we used pre-estimated weighting
of the individual sub-items (raspberries, blueberries etc.)
to calculate a combined FRAP value. When an FFQ item
did not have a specified FRAP value, the value was im-
puted based on knowledge of foods and beverages with
similar antioxidant profiles. FRAP values were assigned
to supplements in the same manner. All analyses of
FRAP were performed at the Institute of Nutrition Re-
search, University of Oslo.
To calculate each participant’s total antioxidant capacity
intake (TAC), the frequency of consumption of each item
was multiplied by its FRAP value and summed across all
items consumed. Three exposure variables for TAC intake
were created: 1) Dietary TAC from all foods and beverages;
2) TAC from fruit and vegetables only; and 3) TAC from
dietary supplements. We used data from the Swedish
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National Food Administration to calculate total energy in-
take and intake of nutrients based on the questionnaire
data. TAC and nutrient intakes were energy-adjusted using
the residual method [8, 13]. We also examined the intake
of the main contributors to TAC and their relation to pros-
tate cancer risk.
Statistical analysis
Participants were divided into quintiles of TAC intake
from all foods and from fruit and vegetables giving five
levels of intake for these exposure variables. In addition
we wanted to test whether the extreme low and high in-
takes of TAC were associated with disease and performed
the calculation based on decile distribution of TAC intake.
For TAC from supplements, the non-users comprised the
referent group, and the users were categorized at the me-
dian intake, giving three levels of intake. This was due to
the relatively large number of non-supplement users in
this population. We used unconditional logistic regression
models with indicator variables for each level of TAC in-
take, and for each intake category of the main contributors
to TAC. Age group and region, matching factors in the
study, were included in all models. The fully adjusted
models also included: smoking status (never, former,
current), BMI (<20, 20–22.5, 22.5–<25, 25–<27.5, 27.5–
<30, >30 kg/m2), education (0–9 years, 10–12 years, 13+
yrs), and total energy intake (quartiles). Other potential
confounders were tested in the model, including: civil/
marital status, employment status, family history of pros-
tate cancer, physical activity, as well as intake of alpha-
linolenic acid, vitamin-D, calcium, phytoestrogens, red
meat, fish and dairy products. None of these were in-
cluded in the final models as they had no or little effect on
the effect estimates or precision.
To test for dose–response trends across the levels of
TAC exposures and categories of TAC contributors, we
modeled all exposure variables as continuous variables
using the median intake in each quintile, decile or category
of intake. Analyses of the major contributors to dietary
TAC (coffee, tea, berries, chocolate and boiled potatoes)
were mutually adjusted, in addition to including the factors
in the original TAC model, as well as adjusting for zinc
and calcium intake. Similarly, the models for major con-
tributors to supplemental TAC (Vitamin C supplements
and multivitamins) were mutually adjusted, and included
the same factors as the models for major contributors to
dietary TAC. The analysis of intake of TAC and prostate
cancer were also performed in subgroups as never smokers
and ever smokers.
Advanced prostate cancer was defined as cancer with
capsule penetration or seminal vesicle infiltration (T3), in-
vasion of adjacent organs (T4), metastasis to lymph nodes
(N+) or distant organs (M1) at the time of diagnosis, or
prostate cancer death during follow-up through June 2009.
Fatal cases, a subgroup of advanced cases, were defined as
participants that died from the disease during follow-up.
Localized cases were those with T1 and T2 tumors and no
metastases (N0/M0) at the time of diagnosis. Since ad-
vanced and lethal disease cases would include cases that
died during follow-up, the categories localized and ad-
vanced are not mutually exclusive, and therefore the sum of
advanced and localized exceeding the total number of cases.
High grade cases included those with Gleason score 8–10,
and low grade cases included cases with Gleason score 2–6.
Gleason score 7 cases were not included in either high-
grade or low-grade disease because of the heterogeneity of
these tumors, and the different outcomes seen for Gleason
3 + 4 compared to Gleason 4 + 3 [6, 8, 14].
Results
Descriptive data
The main contributors to dietary TAC intake in the
study population were coffee (62 %), tea (4 %), berries
(4 %), chocolate (2 %) and boiled potatoes (2 %). Mean
intake of TAC from diet was similar among controls and
cases, 22.2 and 22.6 mmol/day respectively, and TAC
from fruit and vegetables was 3.5 mmol/day among both
cases and controls (Table 1). Among controls the mean
intake of TAC from supplements was 0.6 mmol/day com-
pared to 0.8 mmol/day among cases. We found no appre-
ciable differences between controls and cases regarding
BMI, smoking habits, and intake of energy, calcium and
zinc. Multivitamin, supplemental vitamin C and supple-
mental vitamin E use was more common among cases
compared to controls and high grade cases used more
multivitamins compared to controls. Intake of the major
contributors to dietary TAC was similar across disease
categories, except coffee and tea intakes that were slightly
lower in high grade and fatal cases (Table 2).
TAC and prostate cancer risk
Dietary TAC and TAC from fruit and vegetables only were
not significantly associated with prostate cancer risk
(Table 3). To investigate whether the extreme high and
low intakes of TAC were associated with all incident pros-
tate cancer we calculated odds ratios based on decile
distribution for the exposure variables dietary TAC (OR =
1.03, 95 % CI 0.72–1.48 and TAC from fruit and vegeta-
bles (OR = 0.88, 95 % CI 0.61–1.26) respectively between
lowest and highest decile of intake.
We performed a stratified analysis of TAC intake from
diet and fruit and vegetables in ever smokers and never
smokers. No appreciable differences were observed com-
pared to the total population. For dietary TAC and TAC
from fruit & vegetables among ever smokers the odds
ratios in the highest quintile compared to the lowest
quintile was: 1.12, (95 % CI 0.87–1.65) and 0.95 (95 %
CI 0.69–1.31) respectively. Furthermore among never
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smokers the odds ratios in the highest quintile compared
with the lowest was for dietary TAC 0.69, (95 % CI
0.45–1.07) and TAC from fruit & vegetables 0.96, (95 %
CI 0.63–1.48) respectively.
Supplement use was more common among cases com-
pared to controls, and consequently, we found a positive
association between highest level of TAC intake from
supplements and total, advanced, localized, high grade
and low grade prostate cancer (total: OR = 1.37, 95 % CI
1.08–1.73, advanced: 1.51, 95 % CI 1.11–2.06, localized:
1.36, 95 % CI 1.06–1.76, high grade: 1.60, 95 % CI 1.06–
2.40, low grade: 1.36, 95 % CI 1.03–1.81).
The major contributors to TAC derived from supple-
ments were multivitamins and vitamin C. We observed a
positive association with use of the highest doses of multi-
vitamins and total (OR = 1.27, 95 % CI: 1.01–1.60) and
high grade prostate cancer risk (1.93, 95 % CI: 1.32–2.81)
(Table 4), whereas no association was seen for vitamin C
supplements. To investigate if the findings for multivita-
min use could be the result of reverse causation, (i.e., men
began taking supplements as a result of feeling poorly due
to disease prior to diagnosis), we took into account the
duration of supplement use (vitamin C and multivitamins)
and divided subjects into four groups: Never users, short-
term users (0–2 years), intermediate-term users (2–5
years) and long-term users (>5 years). We found a positive
association for longer duration of multivitamin use and
risk of advanced (OR = 1.56, 95 % CI 1.02–2.40) and high-
grade prostate cancer (2.00, 95 % CI 1.20–3.36) respect-
ively for long-term users versus never users. For vitamin
C use, we found a significantly increased risk of total,
advanced and fatal prostate cancer among long-term com-
pared to never users (total: OR = 1.32, 95 % CI 1.04–1.66,
advanced 1.52, 95 % CI 1.03–2.23, fatal 1.23, 95 % CI
1.06–2.02).
Components of dietary TAC and prostate cancer
For the main contributors to dietary TAC intake there
were some notable associations with prostate cancer
(Table 4). As previously published for this population,
coffee intake was inversely associated with risk of fatal
and high grade prostate cancer [15]. Following mutual
adjustment for the other contributors to TAC we found
an inverse association between coffee intake and fatal
and high grade prostate cancer with 45–55 % lower OR
for fatal and high grade prostate cancer, comparing the
highest category of intake (≥6cups/day) to those in the
lowest category of intake. For tea intake we observed a
similar association, although weaker and based on fewer
participants with high intakes. For berry intake we saw
no significant inverse association. For chocolate intake,
there was a positive association with total, advanced, lo-
calized and low grade prostate cancer (total OR = 1.43,
95 % CI 1.12–1.82, advanced 1.40, 95 % CI 1.01–1.96, lo-
calized 1.43, 95 % CI 1.08–1.88, and low grade 1.41,
95 % CI 1.03–1.93). For boiled potatoes, there was no
significant trend across categories of intake.
Discussion
In this large Swedish population-based study, we found
no convincing association between TAC from all foods
or from fruit and vegetables only and overall prostate
cancer. Other studies examining the risk of prostate can-
cer with a combined score of antioxidants and pro oxi-
dants, also reported null results [1, 16]. The assessment
of the total dietary antioxidant capacity captures both all
known and unknown antioxidants, which should be
more informative than analyses of single antioxidants.
Studies of total antioxidant intake utilizing the FRAP
assay have been negative for colorectal and endometrial
cancer. But for gastric cancer, an inverse association has
been documented between high intake of antioxidants
from plant foods assessed by the FRAP assay and disease
risk [17–20].
One possible reason for the lack of overall association
for TAC intake from diet and prostate cancer in our
Table 1 Age standardized study population characteristic by
controls and cases in means (standard deviations) or percents,
Cancer of the Prostate Sweden Study
Controls Cases
N 1112 1489
FRAP diet (mmol/d) 22.2 (8.6) 22.3 (8.4)
FRAP fruit/vegs (mmol/d) 3.5 (1.8) 3.5 (1.7)
FRAP suppl. (mmol/d) 0.6 (1.2) 0.8 (1.4)
Age 67.7 (7.5) 66.8 (7.3)
BMI 26(3) 26(3)
Current smokers (%) 12 11
Never smokers (%) 38 39
0–9 yrs education (%) 46 46
10–12 years education (%) 42 40
13+ yrs education (%) 11 14
Energy kcal/d) 2218 (655) 2283 (646)
Coffee (cups/day) 3.1 (2.0) 3.1 (1.9)
Tea (cups/day) 0.6 (1.0) 0.7 (1.0)
Chocolate (serv./d) 0.2 (0.2) 0.2 (0.3)
Berries (serv./d) 0.2 (0.2) 0.2 (0.2)
Boiled potatoes (serv./d) 0.6(0.4) 0.6(0.4)
Multivitamin use (%) 16 22
Vitamin C suppl. use (%) 12 15
Vitamin E suppl. use (%) 3 4
Calcium (mg/d) 1197 (363) 1199 (370)
Zinc (mg/d) 11.7 (1.8) 11.6 (1.9)
PSA at diagnosis 89 (360)
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study may be that some of the main contributors to the
antioxidant intake had opposite associations with pros-
tate cancer risk. Coffee, chocolate and berries were
among the five major contributors, but as chocolate in-
take was positively associated with total, advanced, local-
ized and low grade prostate cancer risk, the intake of
coffee and berries seemed to be inversely associated with
some of the disease sub-types.
TAC from coffee was suggestively associated with re-
duced risk for fatal and high grade cancer, which is in line
with other population based studies [6, 15, 21, 22]. Re-
cently several meta analyses have shown an inverse associ-
ation between coffee consumption and prostate cancer,
especially fatal and high grade cancers [23–26]. However,
the composition of the diet with respect to TAC intake
was different in the CAPS study compared to the Health
Professionals Follow-up Study (HPFS) in the U.S. In the
former study coffee contributed to 62 % of dietary TAC in-
take but only 28 % in the latter. The coffee intake in
Sweden is considerably higher than in the US. Swedish per
capita coffee consumption is 7.14 kg/year compared to the
US with only 4.24 kg /year (2011) [27]. This may also re-
flect that overall total antioxidant intake in Sweden is
somewhat higher compared with other populations:
Among cases and controls in this study the daily average
intake (energy adjusted) was 22.3 mmol/d and 22.2 mmol/
d respectively. In the US population Health Professionals
Follow up Study, the daily average intake of TAC from diet
was 10.8 mmol/d [8]. In an Italian Study population the
mean levels of total antioxidant intake from diet was
11.45 mmol/d utilizing the FRAP assay, but the authors
did not include coffee in their calculation which may have
resulted in an underestimation of the overall intake [28].
Other studies have used different units to quantify the anti-
oxidant intake, making comparisons difficult [29].
The proportion of patients diagnosed with a higher clin-
ical stage (T3, T4, N1 or M1) in the CAPS study was
almost twice the proportion in the HPFS (33 % vs. 16 %)
probably due to more extensive PSA screening in the U.S.
The observed association with chocolate could be bio-
logically plausible, because the high amount of carbohy-
drates in chocolate could stimulate IGF-1 production as
Table 2 Age standardized study population characteristic by subtypes of cases in means (standard deviations) or percents, Cancer
of the Prostate Sweden Study
Fatal Advanced Localized High grade Low grade
N 307 499 1020 231 693
FRAP diet (mmol/d) 21.6 (7.9) 22.5 (8.9) 22.2 (8.1) 21.3 (8.0) 22.3 (8.0)
FRAP fruit/vegs (mmol/d) 3.5 (1.9) 3.4 (1.7) 3.5 (1.7) 3.6 (2.0) 3.4 (1.6)
FRAP suppl. (mmol/d) 0.7 (1.2) 0.8 (1.4) 0.9 (1.4) 0.9 (1.3) 0.8 (1.4)
Age 67.0(7.3) 68.6 (7.4) 66.0 (7.1) 68.3 (7.4) 65.4 (7.0)
BMI 26 (3) 26 (3) 26 (3) 26 (3) 26 (4)
Current smokers (%) 14 13 10 12 10
Never smokers (%) 42 39 39 41 38
0–9 years education (%) 53 51 44 48 44
10–12 years education (%) 37 41 40 40 41
13+ yrs education (%) 10 8 17 13 16
Energy kcal/d) 2363 (701) 2334(681) 2270 (630) 2387(655) 2234 (624)
Coffee (cups/day) 3.1 (1.8) 3.2(2.0) 3.1 (1.9) 3.0 (1.9) 3.1 (1.8)
Tea (cups/day) 0.5 (0.8) 0.5 (0.9) 0.7 (1.1) 0.6 (0.8) 0.7 (1.1)
Chocolate (serv./d) 0.2 (0.3) 0.2 (0.3) 0.2 (0.2) 0.2 (0.2) 0.2 (0.2)
Berries (serv./d) 0.2 (0.3) 0.2 (0.2) 0.2 (0.3) 0.2 (0.3) 0.1 (0.2)
Boiled potatoes (serv./d) 0.6(0.4 0.6 (0.4) 0.6 (0.4) 0.6 (0.3) 0.6 (0.4)
Multivitamin use (%) 21 22 21 29 20
Vitamin C suppl. use (%) 12 15 15 16 14
Vitamin E suppl. use (%) 3 3 4 3 5
Calcium (mg/d) 1241(406) 1222 (390) 1188 (363) 1213 (381) 1193 (363)
Zinc (mg/d) 11.5 (1.9) 11.5 (1.9) 11.6 (1.9) 11.6 (1.9) 11.7 (1.8)
PSA at diagnosis 264 (573) 276 (665) 39 (241) 167 (364) 22 (136)
Fatal prostate cancer: Death from prostate cancer through follow up. Advanced prostate cancer: M1, N1, T3 or T4 and death during follow up. Localized prostate
cancer: T1 or T2 and N0/M0. High-grade prostate cancer: Gleason sum 8–10. Low-grade prostate cancer: Gleason sum 2–6
Russnes et al. BMC Cancer  (2016) 16:438 Page 5 of 12
a possible mechanism contributing to increased tumor
growth and a more malignant behavior of the disease
[30, 31]. In one study, sucrose intake and disaccharides
was positively associated with prostate cancer risk [32].
However two large prospective studies found no
association between glycemic index and prostate cancer
risk [33, 34]. On the other hand, dark chocolate is also
high in flavonoids, a potent group of antioxidants [12],
but there was no distinction between different types of
chocolate in the CAPS questionnaire. The most likely
Table 3 Odds ratios, OR (and 95 % CI) of prostate cancer by quintiles of TAC all foods, TAC from fruits and vegetables, Cancer of the
Prostate Sweden
FRAP food only Q1 Q2 Q3 Q4 Q5 p-t rend
All prostate cancer 294/226 292/228 301/220 308/212 294/226
Age and region adjusted OR 1.00 1.02 (0.80–1.31) 1.08 (0.84–1.39) 1.11 (0.87–1.43) 1.02 (0.79–1.31) 0.76
Fully adjusted OR 1.00 0.98(0.77–1.26) 1.05 (0.82–1.35) 1.09 (0.85–1.40) 1.05 (0.82–1.36) 0.53
Lethal prostate cancer 51/226 49/228 49/220 42/212 41/226
Age and region adjusted OR 1.00 0.98 (0.63–1.51) 1.01(0.65–1.56) 0.91 (0.58–1.43) 0.89 (0.57–1.43) 0.58
Fully adjusted OR 1.00 0.98 (0.63–1.53) 0.98(0.63–1.53) 0.92 (0.58–1.45) 0.87 (0.55–1.39) 0.52
Advanced prostate cancer 94/226 103/228 95/220 102/212 105/226
Age and region adjusted OR 1.00 1.11 (0.78–1.55) 1.04(0.74–1.47) 1.20 (0.85–1.68) 1.23 (0.88–1.73) 0.20
Fully adjusted OR 1.00 1.08 (0.77–1.53) 1.02(0.72–1.44) 1.18 (0.83–1.67) 1.23 (0.87–1.74) 0.21
Localized prostate cancer 201/226 196/228 216/220 212/212 195/226
Age and region adjusted OR 1.00 1.01 (0.77–1.33) 1.16 (0.89–1.53) 1.11 (0.84–1.46) 0.96 (0.73–1.26) 0.90
Fully adjusted OR 1.00 0.96 (0.73–1.27) 1.12 (0.85–1.47) 1.09 (0.82–1.43) 1.00 (0.75–1.32) 0.80
High-grade prostate cancer 56/226 39/228 47/220 49/212 40/226
Age and region adjusted OR 1.00 0.72 (0.46–1.13) 0.88(0.57–1.36) 0.99(0.64–1.52) 0.79(0.50–1.25) 0.64
Fully adjusted OR 1.00 0.68 (0.43–1.07) 0.83(0.53–1.28) 0.95(0.61–1.48) 0.78(0.49–1.24) 0.63
Low–grade prostate cancer 134/226 139/228 136/220 146/212 138/226
Age and region adjusted OR 1.00 1.06 (0.78–1.44) 1.07 (0.78–1.45) 1.11 (0.81–1.50) 0.99 (0.72–1.35) 0.22
Fully adjusted OR 1.00 1.02 (0.75–1.39) 1.03 (0.76–1.41) 1.09 (0.80–1.49) 1.04 (0.76–1.42) 0.74
FRAP fruit & vegetables Q1 Q2 Q3 Q4 Q5 p-trend
All prostate cancer 297/222 277/243 306/213 311/209 295/224
Age and region adjusted OR 1.00 0.84(0.66–1.08) 1.06(0.82–1.36) 1.09(0.85–1.39) 0.97(0.76–1.25) 0.50
Fully adjusted OR 1.00 0.83(0.64–1.07) 1.04(0.80–1.34) 1.07(0.83–1.38) 0.94(0.73–1.22) 0.82
Lethal prostate cancer 53/222 33/243 52/213 45/209 48/224
Age and region adjusted OR 1.00 0.57 (0.36–0.92) 1.01 (0.65–1.54) 0.91 (0.58–1.41) 0.91 (0.59–1.41) 0.74
Fully adjusted OR 1.00 0.61 (0.38–0.99) 1.13 (0.73–1.77) 1.07 (0.67–1.71) 1.02 (0.65–1.61) 0.39
Advanced prostate cancer 114/222 77/243 106/213 98/209 102/224
Age and region adjusted OR 1.00 0.64 (0.44–0.94) 0.90(0.63–1.30) 0.92(0.64–1.33) 0.91(0.63–1.30) 0.76
Fully adjusted OR 1.00 0.65(0.46–0.93) 1.01(0.72–1.41) 1.01(0.71–1.42) 0.96(0.68–1.35) 0.49
Localized prostate cancer 192/222 204/243 205/213 219/209 199/224
Age and region adjusted OR 1.00 0.93 (0.71–1.23) 1.09 (0.83–1.44) 1.15 (0.87–1.51) 1.00 (0.76–1.32) 0.67
Fully adjusted OR 1.00 0.90 (0.68–1.18) 1.04 (0.79–1.38) 1.07 (0.81–1.42) 0.94 (0.71–1.25) 0.95
High-grade prostate cancer 53/222 27/243 46/213 45/209 58/224
Age and region adjusted OR 1.00 0.47(0.28–0.77) 0.88 (0.57–1.37) 0.89 (0.57–1.39) 1.08 (0.71–1.64) 0.12
Fully adjusted OR 1.00 0.49(0.30–0.82) 0.93 (0.59–1.46) 0.99 (0.62–1.57) 1.13 (0.73–1.76) 0.08
Low-grade prostate cancer 129/222 149/243 140/213 150/209 124/224
Age and region adjusted OR 1.00 0.99 (0.73–1.34) 1.06 (0.78–1.45) 1.15 (0.85–1.57) 0.91 (0.66–1.24) 0.67
Fully adjusted OR 1.00 0.94 (0.69–1.28) 1.01 (0.73–1.38) 1.09 (0.80–1.50) 0.85 (0.62–1.18) 0.46
Fully adjusted models are adjusted for: age, region, smoking (never, former, current), BMI (categories), education (categories), and energy intake (categories)
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Table 4 Odds ratios, OR (and 95 % CI) of prostate cancer by major contributors to TAC: coffee, tea, berries, chocolate, boiled potatoes, multivitamins and vitamin C supplements,
Cancer of the Prostate Sweden
Coffee None <2 cups/day 2–3cups/day 4–5cups/day ≥6 cups/day p-trend
All prostate cancer 139/98 150/121 644/491 413/295 143/107
Fully adj. OR 1.00 0.88(0.61–1.26) 0.93(0.69–1.26) 1.03(0.75–1.42) 0.95(0.64–1.40) 0.87
Fatal prostate cancer 14/44 32/175 103/491 68/295 15/107
Fully adj. OR 1.00 0.58(0.31–1.07) 0.73(0.45–1.18) 0.87(0.52–1.44) 0.56(0.29–1.08) 0.51
Advanced prostate cancer 47/121 47/121 207/491 151/295 53/107
Fully adj. OR 1.00 0.90(0.54–1.52) 0.92(0.60–1.41) 1.09(0.70–1.72) 1.00(0.58–1.71) 0.65
Localized prostate cancer 98/98 103/121 452/491 273/295 94/107
Fully adj. OR 1.00 0.86(0.57–1.28) 0.98(0.70–1.36) 1.04(0.72–1.48) 0.93(0.60–1.44) 0.86
High grade prostate cancer 30/98 22/121 98/491 62/295 19/107
Fully adj. OR 1.00 0.53(0.28–1.01) 0.55(0.33–0.92) 0.59(0.24–1.01) 0.45(0.22–0.90) 0.05
Low grade prostate cancer 55/98 79/121 313/491 177/295 69/107
Fully adj. OR 1.00 1.22(0.77–1.94) 1.22(0.82–1.80) 1.21(0.79–1.84) 1.24(0.76–2.05) 0.60
Tea None <1cup/day 1–2 cups/day >2 cups/day
All prostate cancer 605/484 370/262 439/310 75/56
Fully adj. OR 1.00 1.12(0.91–1.37) 1.09(0.89–1.34) 0.97(0.65–1.44) 0.98
Fatal prostate cancer 142/484 73/262 83/310 9/56
Fully adj. OR 1.00 0.95(0.66–1.36) 0.90(0.64–1.26) 0.60(0.28–1.30) 0.16
Advanced prostate cancer 230/484 131/262 121/310 17/56
Fully adj. OR 1.00 1.06(0.81–1.40) 0.86(0.64–1.15) 0.67(0.37–1.23) 0.12
Localized prostate cancer 390/484 251/262 318/310 61/56
Fully adj. OR 1.00 1.15(0.92–1.45) 1.20(0.96–1.50) 1.12(0.74–1.70) 0.38
High grade prostate cancer 94/484 65/262 63/310 9/18
Fully adj. OR 1.00 1.27(0.88–1.83) 0.92(0.63–1.36) 0.64(0.29(1.40) 0.17
Low grade prostate cancer 265/484 166/262 221/310 41/56
Fully adj. OR 1.00 1.12(0.86–1.45) 1.25(0.97–1.62) 1.12(0.70–1.81) 0.33
Berries None 1–3 /month >1–3/month
All prostate cancer 276/231 739/482 474/399
Fully adj. OR 1.00 1.16(0.93–1.44) 0.90(0.70–1.44) 0.08
Fatal prostate cancer 67/231 129/482 610/399











Table 4 Odds ratios, OR (and 95 % CI) of prostate cancer by major contributors to TAC: coffee, tea, berries, chocolate, boiled potatoes, multivitamins and vitamin C supplements,
Cancer of the Prostate Sweden (Continued)
Advanced prostate cancer 98/231 236/482 164/399
Fully adj. OR 1.00 1.15(0.85–1.55) 0.90(0.65–1.25) 0.15
Localized prostate cancer 186/321 513/482 321/399
Fully adj. OR 1.00 1.16(0.91–1.49) 0.89(0.68–1.16) 0.11
High grade prostate cancer 38/231 104/482 89/399
Fully adj. OR 1.00 1.19(0.78–1.83) 1.10(0.70–1.72) 0.91
Low grade prostate cancer 133/231 370/482 190/399
Fully adj. OR 1.00 1.17(0.89–1.53) 0.75(0.56–1.02) <0.01
Chocolate None 1–3/month >1–3/month
All prostate cancer 232/258 645/457 612/397
Fully adj. OR 1.00 1.38(1.09–1.73) 1.43(1.12–1.82) 0.03
Fatal prostate cancer 59/258 119/457 129/397
Fully adj. OR 1.00 1.26(0.86–1.85) 1.47(0.99–2.20) 0.09
Advanced prostate cancer 93/258 194/457 212/397
Fully adj. OR 1.00 1.19(0.86–1.63) 1.40(1.01–1.96) 0.06
Localized prostate cancer 146/258 463/457 411/397
Fully adj. OR 1.00 1.46(1.13–1.89) 1.43(1.08–1.88) 0.11
High grade prostate cancer 42/258 88/457 101/397
Fully adj. OR 1.00 1.04(0.67–1.60) 1.20(0.77–1.88) 0.33
Low grade prostate cancer 102/258 310/457 281/397
Fully adj. OR 1.00 1.38(1.03–1.85) 1.41(1.03–1.93) 0.09
Boiled potatoes 0–4×/w 4–6×/w ≥1×/day
All prostate cancer 266/195 668/545 555/372
Fully adj. OR 1.00 0.92(0.73–1.16) 1.12(0.87–1.42) 0.21
Fatal prostate cancer 42/195 151/545 114/372
Fully adj. OR 1.00 1.27(0.85–1.90) 1.31(0.86–2.01) 0.26
Advanced prostate cancer 86/195 219/545 194/372
Fully adj. OR 1.00 0.88(0.64–1.20) 1.07(0.77–1.49) 0.45
Localized prostate cancer 181/195 464/545 375/372
Fully adj. OR 1.00 1.00(0.79–1.29) 1.20(0.92–1.57) 0.13











Table 4 Odds ratios, OR (and 95 % CI) of prostate cancer by major contributors to TAC: coffee, tea, berries, chocolate, boiled potatoes, multivitamins and vitamin C supplements,
Cancer of the Prostate Sweden (Continued)
Fully adj. OR 1.00 1.18(0.75–1.84) 1.33(0.83–2.12) 0.21
Low grade prostate cancer 134/195 107/545 91/372
Fully adj. OR 1.00 0.90(0.68–1.19) 1.07(0.79–1.45) 0.45
Multivitamins None <7/week ≥7/week
All prostate cancer 1166/930 69/32 254/150
Fully adj. OR 1.00 1.48(0.95–2.30) 1.27(1.01–1.60) 0.07
Fatal prostate cancer 183/930 12/32 37/150
Fully adj. OR 1.00 1.65(0.84–3.24) 1.37(0.95–1.99) 0.18
Advanced prostate cancer 391/930 24/32 84/150
Fully adj. OR 1.00 1.69(0.97–2.97) 1.29(0.95–1.75) 0.08
Localized prostate cancer 803/930 46/32 171/150
Fully adj. OR 1.00 1.34(0.83–2.17) 1.21(0.94–1.55) 0.18
High grade prostate cancer 165/930 14/32 52/150
Fully adj. OR 1.00 2.20(1.11–4.33) 1.93(1.32–2.81) 0.03
Low grade prostate cancer 552/930 25/32 116/150
Fully adj. OR 1.00 1.08(0.62–1.89) 1.25(0.85–1.85) 0.75
Vitamin C None <7/week ≥7/week
All prostate cancer 1271/984 106/62 112/66
Fully adj. OR 1.00 1.20(0.86–1.68) 1.22(0.88–1.70) 0.14
Fatal prostate cancer 200/984 19/62 13/66
Fully adj. OR 1.00 1.27(0.75–2.16) 0.86(0.47–1.55) 0.19
Advanced prostate cancer 423/984 36/62 40/66
Fully adj. OR 1.00 1.32(0.85–2.06) 1.47(0.96–2.25) 0.14
Localized prostate cancer 866/984 78/62 76/66
Fully adj. OR 1.00 1.25(0.87–1.79) 1.15(0.80–1.65) 0.20
High grade prostate cancer 195/984 21/62 15/66
Fully adj. OR 1.00 1.48(0.86–2,55) 0.93(0.50–1.71) 0.80
Low grade prostate cancer 593/984 43/62 57/66
Fully adj. OR 1.00 0.99(0.65–1.51) 1.25(0.85–1.85) 0.18
Fully adjusted models are adjusted for: age, region, smoking (never, former, current), BMI (categories), education (categories), energy intake, calcium (quartiles), zinc(quartiles). Food models mutually adjusted for











explanation for this association, however is that it is a
chance finding.
Because berries are a rich source of flavonoids, the
trend indicating an inverse association with low-grade
prostate cancer is plausible. Flavonoids are antioxidants
that may inhibit the matrix metalloproteinase system
(MMP) [35, 36], which is probably important in the in-
vasive and metastatic process [37]. The 25 % reduction
of risk for low-grade prostate cancer observed for those
consuming berries more than 1–3 times per month
could possibly be due to this chemopreventive effect.
This novel finding is interesting due to a plausible mech-
anism of action. If a protective effect from substances
abundant in berries exists – it would most likely be weak
and mostly effective in the indolent, low-grade cases
whereas an effect in high-grade cases would not be ex-
pected. In the CAPS questionnaire intake of all berries
were aggregated into one question. This makes it diffi-
cult to determine whether the association was related to
specific berries/phytochemicals or confounded by
healthy lifestyle related behaviors. Furthermore, when
we analyzed TAC from fruit and vegetables, where ber-
ries comprised 23 % of the TAC contribution, we ob-
served no association with prostate cancer.
TAC derived from supplements appeared positively
associated with all categories of prostate cancer, except
fatal cancers. The risk estimates are in line with those
previously found in the Health Professionals Follow-up
Study [8]. However, we cannot rule out reverse caus-
ation, because men who experienced early symptoms of
prostate cancer before diagnosis might have self-
medicated with supplements. High doses of antioxi-
dants taken as supplements may also have pro-oxidant
properties [38, 39], that promote survival of malignant
cells [40]. Recently, it was also shown in animal models,
that dietary antioxidants may interfere with endogenous
antioxidants by affecting feedback mechanisms [41]. All
these explanations fits well with the observation that
most nutrients follow a non-linear, inverted U-shaped
curve with respect to their physiological function, and
hence both deficiencies and high levels may be associ-
ated with disease [42]. Possible explanations for the
differences between this population and the HPFS may
be that almost twice as many individuals were regular
supplement users in the US study population compared
to the participants in CAPS. The long follow up time
with multiple exposure assessments and large numbers
cases with lethal disease in the HPFS can also explain
why this finding was more apparent in the HPFS, com-
pared to the fatal disease studied in CAPS.
In the present study we also had the ability to look
more closely at the major contributors to TAC from
supplements. The associations were mainly accounted
for by multivitamin use, in line with findings in some
other studies [43, 44], although others reported null re-
sults [45, 46]. However, in our study, both analyses on
TAC from supplements and multivitamins must be
interpreted with caution due to the limited number of
supplement users and the possibility of reverse
causation.
We are aware of other limitations in this study. Se-
lection bias is a concern in case–control studies, as
participating controls may be more health conscious
than the general population. In our study, however,
the groups were well balanced with regard to baseline
characteristics. In addition, such selection bias would
not explain our supplement results because dietary
supplement use is associated with more health con-
scious behavior, Recall bias is another concern, be-
cause diet was assessed after the prostate cancer
diagnosis which could give rise to differential mis-
classification of exposure. Reverse causation, especially
in the assessment of supplement use as mentioned
above, may explain the findings associated with TAC
from supplements, since a proportion of the cases may
have experienced disease-related symptoms such as
fatigue and started using supplements due to this
before the time of diagnosis. Multiple testing is always
a concern when assessing many different outcomes.
The lack of association between TAC from diet and
prostate cancer risk could also in part be explained by
the fact that, the FRAP assay only measure in vitro
antioxidant activity and, does not take into account
the diversity in bioavailability of different antioxidants
and their in vivo metabolism.
There are several strengths to this study. The
population-based design with a large number of con-
trols and cases, and information on disease characteris-
tics makes it possible to study not only total prostate
cancer, but also sub-groups of the disease. The large
amount of data collected, including information on diet
and other lifestyle-related habits, makes it possible to
adjust for many possible confounding factors. The
measurement of the total antioxidant capacity in diet
captures both all known and unknown antioxidants,
which may strengthen the associations compared to
examining only single antioxidants.
Conclusion
In conclusion, we found no association between of
total antioxidant capacity and prostate cancer, either
from the total diet or from fruit and vegetables. High
intake of antioxidants from supplements was associ-
ated with increased risk for all subgroups of prostate
cancer, except fatal cancer. This finding must be
interpreted with caution due to the possibility for re-
verse causation.
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